CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
Ritlecitinib 50 mg +1 moredrug
Likely dose
Ritlecitinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05128058
NCT05128058Phase 1Completed
CompareCT.gov

AN OPEN LABEL, PHASE 1, TWO-ARM STUDY TO ASSESS TARGET OCCUPANCY AND FUNCTIONAL INHIBITION OF JAK3 AND TEC KINASES BY SINGLE DOSES OF RITLECITINIB IN HEALTHY ADULT PARTICIPANTS

Pfizer·interventional·Posted Nov 19, 2021·Updated Nov 13, 2023

In Brief

A Phase 1 clinical trial evaluating Ritlecitinib 50 mg and Ritlecitinib 200 mg for Healthy. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This is a phase 1, open label, two-arm study to assess target occupancy and functional inhibition of JAK3 and TEC kinases by Ritlecitinib in healthy adult participants

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedNov 19, 2021
Enrollment StartOct 22, 2021
Primary CompletionJan 14, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.6 years ago

Interventions

Ritlecitinib 50 mgdrug

50 mg single dose

Ritlecitinib 200 mgdrug

200 mg single dose